ReviewFrontiers in neuroscience2026
Neurofilament light chain but not glial fibrillary acidic protein serum levels are elevated in Wolfram syndrome.
Review in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Genotype-Based Severity Scoring System in Wolfram Syndrome: Correlation with Onset of Cardinal Symptoms andmedRxiv : the preprint server for health sciences · 2026Article
- Genotype-based severity scoring system in Wolfram Syndrome: correlation with onset of cardinal symptoms andFrontiers in genetics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Background: Wolfram syndrome is a rare genetic disorder caused by pathogenic variants in the Objective: To determine if serum NfL and/or GFAP levels are elevated in Wolfram syndrome compared to controls and whether they can serve as monitoring biomarkers. Methods: Serum NfL and GFAP levels were log Results: NfL levels were higher in the Wolfram group relative to all control groups ( Conclusion: Serum NfL elevation in Wolfram syndrome may reflect the ongoing, relatively slow neurodegeneration occurring in this disorder. However, without any correspondence between serum levels and currently used clinical and neuroimaging metrics, it has limited utility as a monitoring biomarker of disease progression in this patient population. Future studies may be warranted to determine if NfL could be a treatment-response marker in Wolfram syndrome clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.